Press release
Mesothelioma Pipeline Outlook Report 2025: Key 45+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's "Mesothelioma Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in the mesothelioma pipeline landscape. It covers the Mesothelioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mesothelioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Mesothelioma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Mesothelioma Pipeline Report
* In August 2025, AstraZeneca announced a phase III study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.
* In August 2025, Epizyme Inc. conducted a study that will provide continuing availability to tazemetostat for people who have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy.
* DelveInsight's Mesothelioma pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Mesothelioma treatment.
* The leading Mesothelioma Companies such as Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc., VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp & Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, and Ascentage Pharma Group Inc. and others.
* Promising Mesothelioma Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Ipilimumab, ZD1839, Zometa, Durvalumab , and others.
Learn how leading Mesothelioma Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Mesothelioma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Mesothelioma Emerging Drugs
* Pegargiminase: Polaris Pharmaceuticals
Pegargiminase (ADIPEG 20), is a biologic in late-stage clinical development for a wide range of cancers. It is a novel therapeutic protein being developed for cancers with a unique metabolic trait. Pegargiminase deprives the cancer cells of the amino acid Arginine by converting plasma-borne arginine into citrulline. At the core of their deficiency is a down-regulation of Argininosuccinate Synthase (ASS1), an enzyme needed to synthesize arginine. To survive, the cancer cells must "rewire" their metabolism. This exerts a stress on the cells that renders them more susceptible to conventional chemotherapies. Pegargiminase has also gained Orphan Drug Designation for mesothelioma both in the U.S. and in Europe. Currently, the drug is in Preregistration stage of its development for the treatment of Mesothelioma.
* Volrustomig: AstraZeneca
Volrustomig is an engineered Fragment Crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, volrustomig targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Mesothelioma.
* Tremelimumab: MedImmune LLC
Tremelimumab is a type of monoclonal antibody and a type of immune checkpoint inhibitor. It is a drug that binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat different types of cancer. Tremelimumab is directed against cytotoxic T- lymphocyte-associated protein 4 (CTLA-4). By blocking the activity of CTLA-4, tremelimumab "releases the brakes" on T cell activation and boosts the immune response against cancer cells. It is a fully human monoclonal antibody, which stimulates the immune system to destroy cancer cells through binding to the protein CTLA-4, expressed on the surface of activated T-lymphocytes. Tremelimumab has been granted Orphan Drug Designation and Fast Track Designation form the US Food and Drug Administration. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Mesothelioma.
* TAK-500: Takeda
TAK-500 is a first-in-class STING agonist immunostimulatory antibody drug conjugate (iADC) that delivers dazostinag to CCR2+ myeloid cells in the tumor microenvironment. By targeting the STING pathway and CCR2 expressing myeloid cells, TAK-500 may offer enhanced potency via improved PK and selective delivery. TAK-500 has three possible mechanisms of action: activation of IFN response, reprogramming of suppressive intratumoral CCR2+ myeloid cells, and blockade of suppressive tumor-associated macrophage recruitment. Activation of STING leads to the production of proinflammatory cytokines that activate dendritic cells, macrophages, and natural killer cells, and subsequently mobilize adaptive immune cells against tumor cells. Combining TAK-500 with radiation and/or checkpoint inhibitors led to enhanced antitumor activity in preclinical studies. Dying tumor cells release tumor antigens and tumor-derived cGAMP, which continue to activate the STING pathway. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Mesothelioma.
* RSO-021: RS Oncology LLC
RSO-021 is a naturally occurring, sulfur-rich, cyclic oligopeptide of the thiopeptide class, which covalently inactivates PRX3, leading to catastrophic oxidative stress and cell death. It is a novel first-in-class small molecule that irreversibly binds and inhibits mitochondrial peroxiredoxin 3 (PRX3). Inhibition of the PRX3 antioxidant signaling network in mitochondria results in selective killing of malignant cells by upregulation of oxidative stress; in contrast, healthy tissue is spared. In pre-clinical models RSO-021 reduces tumor growth in mice, sensitizes tumor cells to apoptosis and reduces the expression of pro-metastatic epithelial to mesenchymal (EMT) genes. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Mesothelioma.
The Mesothelioma Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Mesothelioma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mesothelioma Treatment.
* Mesothelioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mesothelioma market.
From early-stage research to late-phase Mesothelioma Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ Mesothelioma Treatment Drugs [https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Mesothelioma Companies
Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc., VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp & Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, and Ascentage Pharma Group Inc. and others.
Mesothelioma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Mesothelioma Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Stay updated with the latest Mesothelioma Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Mesothelioma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Mesothelioma Pipeline Report
* Coverage- Global
* Mesothelioma Companies- Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc., VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp & Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, and Ascentage Pharma Group Inc. and others
* Mesothelioma Therapies- Pembrolizumab, Lenvatinib, Nivolumab, Ipilimumab, ZD1839, Zometa, Durvalumab , and others.
* Mesothelioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Mesothelioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest Mesothelioma Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Mesothelioma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Mesothelioma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Mesothelioma - DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* Pegargiminase: Polaris Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Tremelimumab: MedImmune LLC
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* TAK-500: Takeda
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Mesothelioma Key Companies
* Mesothelioma Key Products
* Mesothelioma- Unmet Needs
* Mesothelioma- Market Drivers and Barriers
* Mesothelioma- Future Perspectives and Conclusion
* Mesothelioma Analyst Views
* Mesothelioma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=mesothelioma-pipeline-outlook-report-2025-key-45-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
                     Copy
                  
                 Please set a link in the press area of your homepage to this press release on openPR.  openPR disclaims liability for any content contained in this release. 
    You can edit or delete your press release Mesothelioma Pipeline Outlook Report 2025: Key 45+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4137648 • Views: …
More Releases from ABNewswire
 
                                            
                                                    Understanding Magnetic Switches: Types, Working Principles, and Applications                                                
                                            
                                        
                                            A magnetic switch is a versatile electrical device that operates by responding to magnetic fields. From Hall Effect to reed switches, explore their functions, types, and diverse applications.
What is a Magnetic Switch?
A magnetic switch is an electrical device that operates by responding to the presence of a magnetic field. It functions by closing or opening its contacts based on the strength of the magnetic field. Specifically, the switch remains closed…  
                                        
                                     
                                            
                                                    Innovating embedded downlight technology: Leading the global trend of intelligen …                                                
                                            
                                        
                                            The strong rise of China's manufacturing industry has profoundly reshaped the technological landscape and development trajectory of embedded downlights. With its unparalleled industrial chain advantages, continuous technological innovation, and significant cost-effectiveness, Chinese enterprises have risen from participants in the global lighting industry to undisputed leaders. This transformation goes far beyond the huge production scale; it lies in the thorough innovation of the core technical content and application boundaries of embedded…  
                                        
                                     
                                            
                                                    North China Electric Power University Foreign Aid Training Program Visits Yiyuan …                                                
                                            
                                        
                                            On July 23, 2025, the Electrical Industry Training Program of North China Electric Power University's Foreign Aid Project visited Yiyuan Technology for an exchange visit. The purpose was to gain in-depth insights into the company's innovations in renewable energy technology promotion and application [https://www.yiyen.com/about/], and to build bridges connecting university-enterprise cooperation with foreign aid initiatives.
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-1.jpg
Image: https://ecdn6.globalso.com/upload/p/1108/image_other/2025-07/scene-3.jpg
Upon arrival, the delegation received a warm welcome from company leadership and the reception…  
                                        
                                     
                                            
                                                    Pure Sine Wave Low Frequency Inverter Charger                                                
                                            
                                        
                                            Pure sine wave low frequency inverter [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] is widely used and suitable for a variety of scenarios. In terms of home backup power, it can provide reliable power during power outages, ensuring that essential appliances such as refrigerators, air conditioners and medical equipment continue to operate . For solar power generation systems, Inverter charger [https://www.yiypower.com/ap-mini-600w-1500w-120v-low-frequency-pure-sine-wave-inverter-charger-product/] can converter DC Power from Battery, which charged by solar panels, into clean alternating current…  
                                        
                                    More Releases for Mesothelioma
                                                    Mesothelioma Pipeline Outlook Report 2024 (Updated)                                                
                                            
                                        
                                            DelveInsight's, "Mesothelioma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Mesothelioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
 
Key Takeaways from the Mesothelioma Pipeline Report
•	DelveInsight's Mesothelioma pipeline report depicts a…  
                                        
                                    
                                                    Mesothelioma Resource Centre Introduced the All Legal Rights and Options Platfor …                                                
                                            
                                        
                                            Mesothelioma Resource Centre announced the platform for all legal rights and options of Asbestos & Mesothelioma. It is the legal and health resources center for all sufferers of mesothelioma cancer, a cancer almost always caused by exposure to asbestos. 
Generally, a mesothelioma victim must immediately seek redress once diagnosed with the cancer because if the disease has been established to be work-related and the responsible company is identified, a mesothelioma…  
                                        
                                    
                                                    New Mesothelioma Treatment Technique Developed                                                
                                            
                                        
                                            Extrapleural pneumonectomy, a surgical procedure that removes mesothelioma cancer from the lining of the lung, has been reported to be an effective new mesothelioma treatment technique. The technique was developed by Dr. Sugarbaker, the co-leader of the Brigham Biomedical Research Institute's Cancer Research Center, Chief of the Institute's Division of Thoracic Surgery and a Professor of Oncologic Surgery at Harvard Medical School.
The surgical technique was applied on a mesothelioma patient…  
                                        
                                    
                                                    Mesothelioma Cancer: Possible Treatment Option                                                
                                            
                                        
                                            An experiment carried out in Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and the Medical University Vienna has tested the effectiveness of a genetically modified virus to treat mesothelioma in animals. The virus is known as Newcastle Disease Virus (NDV). Animals with mesothelioma administered with multiple doses of NDV responded better than those that received a single dose.
The use of a genetically engineered virus to disrupt the function…  
                                        
                                    
                                                    Veteran Passed Away from Mesothelioma Cancer                                                
                                            
                                        
                                            It has been reported that a U.S. Army veteran passed away at the age of 64 from the asbestos cancer, malignant mesothelioma. He retired from the U.S. Army Corps of Engineers after 25 years of service. Prior to his military career, he worked at a steel company. It is likely that his mesothelioma was caused by asbestos exposure that he encountered at the steel company and during military service.
Malignant mesothelioma…  
                                        
                                    
                                                    Weitz & Luxenberg Mesothelioma Lawyers win $1.28 Million Settlement in Mesotheli …                                                
                                            
                                        
                                            Weitz & Luxenberg mesothelioma lawyers recently secured a $1.28 million settlement for a 77-year-old former carpenter suffering from the asbestos cancer, mesothelioma. Prior to this settlement, Weitz & Luxenberg obtained $842,000 from another defendant.  
The former carpenter is the father of six children and devoted his 30-year career to beautifying such New York City landmarks as Yankee Stadium and the Empire State Building. He was diagnosed with mesothelioma in…  
                                        
                                    